Presentation
7 March 2023 In-vivo fluorescence lifetime tomography for detection and quantification of immunotherapy marker, PD-L1
Author Affiliations +
Abstract
Programed death ligand-1 (PD-L1) expression is currently the only predictive biomarker for cancer immunotherapy. Since PD-L1 expression in tumors is largely heterogeneous, in-vivo detection and quantification of PD-L1 in intact tumors is of major interest. Here we employ fluorescence lifetime (FLT) imaging for in-vivo detection and quantification of PD-L1 expression using an anti-PD-L1 antibody conjugated to IRDye800CW (αPDL1-800). We show that FLT imaging accurately identifies heterogeneous PD-L1 expression in tumors. Tumor areas of high PD-L1 levels were spatially correlated to significantly longer FLTs of αPDL1-800 and the distribution of PD-L1 in deep-seated (>1cm depth) tumors was achieved using FLT tomography.
Conference Presentation
© (2023) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Rahul Pal, Aya Matsui, Murali K., Satoru Morita, Homan Kang, Hak Soo Choi, Dan G. Duda, and Anand Kumar "In-vivo fluorescence lifetime tomography for detection and quantification of immunotherapy marker, PD-L1", Proc. SPIE PC12376, Optical Tomography and Spectroscopy of Tissue XV, PC123760P (7 March 2023); https://doi.org/10.1117/12.2650664
Advertisement
Advertisement
KEYWORDS
In vivo imaging

Tumors

Luminescence

Tomography

Fluorescence tomography

Liver

Biopsy

Back to Top